Showing results (181-190 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|September 4, 2025
A phase 1b/2 study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer and no mutations in DNA damage response genesKaren A Autio, Christos E Kyriakopoulos, Paul Palyca, et al.
Investigational New Drugs|July 1, 2015
Differential nucleobase protection against 5-fluorouracil toxicity for squamous and columnar cells: implication for tissue function and oncogenesisJohn P Vanden Heuvel, Jerry T Thompson, Prajakta Albrecht, et al.
Investigational New Drugs|July 1, 2015
Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancerSara M Tolaney, Sally Tan, Hao Guo, et al.
Investigational New Drugs|June 4, 2020
The old CEACAMs find their new role in tumor immunotherapyZi-Wen Han, Zhi-Wu Lyv, Bin Cui, et al.
Investigational New Drugs|August 21, 2021
In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK)Georgina Meneses-Lorente, Stephen Fowler, Elena Guerini, et al.
Investigational New Drugs|August 3, 2021
Investigating the natural history and prognostic nature of NTRK gene fusions in solid tumorsLimin Zhu, Brian Hobbs, Jason Roszik, et al.
Investigational New Drugs|September 3, 2021
Antineoplastic activity of products derived from cellulose-containing materials: levoglucosenone and structurally-related derivatives as new alternatives for breast cancer treatmentDamian Ignacio Delbart, German Francisco Giri, Agostina Cammarata, et al.
Investigational New Drugs|December 1, 1987
Structure and activity relationship of several novel CC-1065 analogsL H Li, T L Wallace, T F DeKoning, et al.
Investigational New Drugs|August 6, 2022
Phase I study of envafolimab (KN035), a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumorsToshio Shimizu, Takako Eguchi Nakajima, Noboru Yamamoto, et al.
Investigational New Drugs|August 6, 2022
Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumorsXiaofei Zhou, Ulka Vaishampayan, Devalingam Mahalingam, et al.
Pageof 372